SCHEMBL2272853

SCHEMBL2272853

O=C(Nc1cc(-c2ccc(-n3cccc3)cc2)ccc1C(=O)O)c1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACLY P53396 2/20 0.60
SERPINE1 P05121 4/20 0.59
MEN1 O00255 2/20 0.55
PKM P14618 2/20 0.55
KMT2A Q03164 2/20 0.55
MAPT P10636 1/20 0.55
GRIK1 P39086 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
DHODH Q02127 1/20 0.55
HDAC2 Q92769 7/20 0.53
HDAC1 Q13547 2/20 0.53
HDAC3 O15379 1/20 0.52
SUCNR1 Q9BXA5 1/20 0.51
KDM4E B2RXH2 1/20 0.47
ALDH1A1 P00352 1/20 0.47
POLB P06746 1/20 0.47
HPGD P15428 1/20 0.47
MAPK1 P28482 1/20 0.47
HSD17B10 Q99714 1/20 0.47
NPC1 O15118 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2272006 0.96 ACLY (0.62) ACLYSERPINE1MEN1PKMKMT2A
SCHEMBL2273168 0.89 SERPINE1 (0.61) ACLYSERPINE1MEN1PKMKMT2A
SCHEMBL2269037 0.89 ACLY (0.59) ACLYSERPINE1MEN1PKMKMT2A
SCHEMBL14428491 0.86 SERPINE1 (0.53) ACLYSERPINE1MEN1KMT2ADHODH
SCHEMBL2275453 0.86 ACLY (0.76) ACLYSERPINE1MEN1PKMKMT2A
SCHEMBL2273186 0.84 ACLY (0.68) ACLYSERPINE1MEN1PKMKMT2A
SCHEMBL2274895 0.83 ACLY (0.56) ACLYSERPINE1MEN1PKMKMT2A
SCHEMBL2270222 0.83 DHODH (0.77) ACLYSERPINE1MEN1PKMKMT2A
SCHEMBL2274974 0.82 ACLY (0.67) ACLYSERPINE1MEN1PKMKMT2A
SCHEMBL2269268 0.82 ACLY (0.67) ACLYSERPINE1MEN1PKMKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101094829-B novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO.,LTD. (JP) 2012-02-08 CN disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
CN-101094829-A Novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO LTD (JP) 2007-12-26 CN disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 ACLY 653/4885SERPINE1 101/4885MEN1 3105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.